KROS
Keros Therapeutics Inc

1,247
Mkt Cap
$613.28M
Volume
158,516.00
52W High
$22.55
52W Low
$9.12
PE Ratio
13.05
KROS Fundamentals
Price
$20.02
Prev Close
$20.13
Open
$20.20
50D MA
$17.24
Beta
0.89
Avg. Volume
1.33M
EPS (Annual)
-$5.00
P/B
1.16
Rev/Employee
$21,005.92
Loading...
Loading...
News
all
press releases
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
Zacks·3d ago
News Placeholder
More News
News Placeholder
Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros
StoneCo, General Motors, Enersys, Deutsche, Keros have been highlighted in this Screen of The Week article.
Zacks·3d ago
News Placeholder
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.
Zacks·4d ago
News Placeholder
TFG Asset Management GP Ltd Sells 55,000 Shares of Keros Therapeutics, Inc. $KROS
TFG Asset Management GP Ltd reduced its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 30.1% during the second quarter, according to the company in its most recent Form 13F filing...
MarketBeat·6d ago
News Placeholder
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·7d ago
News Placeholder
KROS vs. ARGX: Which Stock Is the Better Value Option?
KROS vs. ARGX: Which Stock Is the Better Value Option?
Zacks·7d ago
News Placeholder
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 67.2% during the second quarter...
MarketBeat·7d ago
News Placeholder
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc.
Federated Hermes Inc. lessened its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 46.6% during the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·7d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Trading Up 12% - Here's Why
Keros Therapeutics (NASDAQ:KROS) Shares Up 12% - Here's Why...
MarketBeat·14d ago
News Placeholder
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00
Bank of America raised their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a "neutral" rating in a report on Friday...
MarketBeat·20d ago
<
1
2
...
>

Latest KROS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.